DOI:

Drug-coated balloons and in-stent restenosis: a new tale of an old story

Roberto Nerla, MD; Antonio Micari, MD, PhD; Alberto Cremonesi*, MD

Multiple studies have shown that nitinol stents improve patency and relieve symptoms more effectively when treating femoral and popliteal obstructions than percutaneous transluminal angioplasty (PTA) alone. However, it is now well known that stents in the superficial femoral artery (SFA) and popliteal arteries are subject to external forces such as bending, twisting, elongation, foreshortening, and external compression1. As a consequence, in-stent restenosis (ISR) has been reported to occur in up to 40% of femoropopliteal lesions treated with metallic stents within one year2,3, with the risk of ISR increasing with lesion length. As the population with femoropopliteal stenting continues to increase, occurrence of ISR has become a clinically relevant problem.

In fact, the treatment of ISR in the femoropopliteal artery is one of the major remaining challenges of endovascular therapy. ISR is often a complex phenomenon that involves both mechanical and biological aspects: first, the presence of long stented segments in femoral arteries is a limit for positive vascular remodelling, which becomes even more true in case of localised fractures and compressions. Second, in the presence of a long stented segment, intimal hyperplasia tends to occur earlier, and dehydration resulting from PTA could accelerate vessel reocclusion.

For all these reasons many factors have to be considered when treating femoropopliteal ISR: the presence of a stenosis versus an occlusion, acute vs. chronic symptoms (suggesting acute thrombus), stent fractures, length of lesion, stent compression, type of stent, location of stent, etc. Consequently, it is very difficult to find a definite treatment able to solve all these issues. Cutting balloon angioplasty has failed to provide durable results4; laser and drug-eluting stents5,6 have shown some encouraging results but the solution is still far off.

In the current issue of EuroIntervention, Cassese et al7 report a meta-analysis aimed at comparing plain balloon angioplasty and drug-coated balloon (DCB) angioplasty in treating femoropopliteal ISR. Putting together the results of small groups of patients, the authors were able to derive outcome considerations that confirm DCB efficacy in femoropopliteal ISR.

The present report adds another piece to the complex puzzle of femoropopliteal interventions: DCB have shown good midterm and long-term outcomes in both short and long femoropopliteal lesions8-11, with the potential advantage of leaving stenting for bail-out situations (i.e., flow-limiting dissections). With the current evidence, DCB should be considered the first strategy in ISR lesions. However, although putting together data is helpful to achieve statistical significance, still there is the risk of merging different scenarios. DCB are safe and effective in promoting an antiproliferative action (in both short- and longer-term follow-ups), but there are still many cases of mechanical stent disruption (e.g., stent fracture, incomplete expansion, etc.) that would hardly benefit from this type of treatment. Further prospective studies possibly enrolling femoropopliteal lesions according to the pathophysiological mechanism of ISR should be undertaken to guide interventionalists in finding a tailored, effective strategy for each clinical scenario.

Conflict of interest statement

The authors have no conflicts of interest to declare.


References

Volume 13 Number 4
Jul 20, 2017
Volume 13 Number 4
View full issue


Key metrics

On the same subject

CLINICAL RESEARCH

10.4244/EIJ-D-16-00735 Jul 20, 2017
Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis
Cassese S et al
free

EXPERT REVIEW

10.4244/EIJ-D-17-00494 Aug 25, 2017
State of the art: balloon catheter technologies – drug-coated balloon
Alfonso F and Scheller B
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved